Lantid 30 mg (Capsule (Enteric Coated))
Medicine Details
Category | Details |
---|---|
Generic | Lansoprazole |
Company | Opsonin pharma ltd |
Indications
- Short-term treatment of active duodenal ulcer
- Maintenance of healed duodenal ulcers
- Short-term treatment of active benign gastric ulcers
- Short-term treatment of active erosive esophagitis
- Maintenance of healing of erosive esophagitis
- Pathological hypersecretory conditions including Zollinger-Ellison Syndrome
- H. pylori eradication to reduce the risk of duodenal ulcer recurrence
Pharmacology
Lansoprazole is a substituted benzimidazole, and is also known as PPI due to its property to block the final step of acid secretion by inhibiting H+/K+ ATPase enzyme system in gastric parietal cell. Both basal and stimulated acid are inhibited.
Dosage & Administration
- 30 mg daily in the morning for benign gastric ulcer for 8 weeks
- 30 mg daily in the morning for duodenal ulcer for 4 weeks; maintenance 15 mg
- 15-30 mg daily for NSAID-associated duodenal or gastric ulcer
- Initially 60 mg once daily for Zollinger-Ellison syndrome; adjusted according to response
- 30 mg daily in the morning for gastroesophageal reflux disease for 4 weeks
- 15-30 mg daily in the morning for acid-related dyspepsia for 2-4 weeks
Interaction
Lantid appears to be a selective inhibitor of the cytochrome P-450 monooxygenase system; there may be an effect on hepatic clearance, but there have been no reports to date of clinically relevant interactions. There is some uncertainty over the effect of Lantid on the oral combined contraceptive pill. Physiological changes similar to those found with omeprazole are likely to occur due to the reduction in gastric acid, which may influence the bacterial colonization of the stomach and duodenum and vitamin B12 absorption.
Contraindications
Lansoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation.
Side Effects
- Possible induction of carcinoid tumors by profound acid suppression
- Rise in serum gastrin levels
- Long-term treatment may accelerate the development of atrophic gastritis
- Dose dependent diarrhea
- Headache
Pregnancy & Lactation
Lansoprazole should be avoided in pregnancy unless there are compelling reasons.
Precautions & Warnings
- Gastric malignancy should be ruled out
- Hepatic impairment
- Pregnancy and lactation
Use in Special Populations
- Neonates: Not recommended
- Children: The youngest person to have received Lantid in clinical trials was 13 years old
- The Elderly: No increase in adverse drug reaction
Therapeutic Class
Proton Pump Inhibitor
Storage Conditions
Store at 25°C
Related Brands
- Lanzol 30 mg (Capsule (Enteric Coated)) - doctors-chemical-works-ltd
- Lasocon 30 mg (Capsule (Enteric Coated)) - biopharma-limited
- Lazo 30 mg (Capsule (Enteric Coated)) - desh-pharmaceuticals-ltd
- Protolan 30 mg (Capsule (Enteric Coated)) - beximco-pharmaceuticals-ltd
- Zoton 30 mg (Capsule (Enteric Coated)) - general-pharmaceuticals-ltd